<DOC>
	<DOCNO>NCT02556307</DOCNO>
	<brief_summary>In Slovenian , multi-center , observational study , effectiveness standard care Peginterferon alfa-2a + ribavirin treatment adult patient chronic hepatitis C ( CHC ) examine . Patients treat 24- 48-weeks , prescribed treat physician , follow 24-week follow-up period .</brief_summary>
	<brief_title>A Study Effectiveness Peginterferon Alfa-2a ( Pegasys ) Ribavirin Treatment Slovenian Hepatitis C ( HCV ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female patient &gt; /= 18 year Positive test HCV Effective contraception specify Peginterferon alfa2a and/or ribavirin label Concomitant infection HIV hepatitis B Participation clinical trial within 30 day prior study start Any contraindication specify Peginterferon alfa2a ribavirin product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>